Cellport Software

Executive Summary

CellPort Software offers a cloud-based SaaS platform that digitizes and automates cell culture, banking, storage, and lab management for life science R&D. Its all-in-one solution standardizes workflows, streamlines compliance, and enhances productivity for biopharma, biotech, CROs, CDMOs, and cellular agriculture firms. Founded in 2014 and headquartered in Boulder, Colorado, the company addresses a critical bottleneck in cell therapy and biologics development—manual, error-prone lab processes. By unifying data and protocols, CellPort enables teams to scale operations while maintaining quality and regulatory readiness. The platform's modular architecture supports GxP environments, making it attractive for both early-stage research and commercial manufacturing. The market for cell-based R&D software is expanding rapidly, driven by the growth of cell and gene therapies, personalized medicine, and cultivated meat. CellPort Software is well-positioned to capture share due to its early mover advantage and focus on usability and compliance. However, as a private company with no disclosed funding or valuation, its growth trajectory remains uncertain. The platform's success hinges on its ability to win enterprise clients and secure capital to fund sales and product expansion. With increasing demand for digital lab solutions, CellPort has significant upside if it can scale effectively.

Upcoming Catalysts (preview)

• Q4 2026GxP Compliance Certification (GLP/GMP)70% success
• Q3 2026Strategic Partnership with a Top 10 CRO60% success
• Q1 2027Series A Fundraising Round Closure50% success